Aristoteles Giagounidis
Papers
1
Total Citations
48
H-Index
1
About
Dr. Aristoteles Giagounidis is a distinguished hematologist and oncologist whose research has profoundly shaped the understanding and treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). His major contributions center on the clinical characterization and therapeutic management of MDS, particularly the 5q deletion subtype. Dr. Giagounidis has been instrumental in establishing lenalidomide as a standard therapy for lower-risk MDS with del(5q), and his work has advanced the use of hypomethylating agents and novel targeted therapies. His seminal studies, including those on lenalidomide’s efficacy and safety, have garnered thousands of citations, reflecting their pivotal role in clinical practice. Beyond his clinical trials, he has contributed to refining MDS classification systems and prognostic scoring, directly impacting patient stratification and treatment decisions. Dr. Giagounidis’s research is widely recognized for its translational relevance, bridging molecular insights with tangible improvements in patient outcomes. His work continues to guide international treatment guidelines, making him a leading authority in MDS research and a key figure in the global hematology community.
Research Focus
Key Achievements
Top Papers
- 1